- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05404880
INSPIRIS Kina PMCF-studie (INSPIRIS China)
Klinisk uppföljningsstudie efter marknaden av Edwards Lifesciences INSPIRIS RESILIA aortaklaff i kinesisk befolkning
The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100037
- Fuwai Hospital, CAMS & PUMC
-
Beijing, Beijing Municipality, Kina, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Fujian
-
Xiamen, Fujian, Kina, 361008
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510080
- The First Affiliated Hospital, Sun Yat-sen University
-
Shenzhen, Guangdong, Kina, 518038
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
-
Henan
-
Zhengzhou, Henan, Kina, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, Kina, 450008
- Henan Provincial Chest Hospital
-
Zhengzhou, Henan, Kina, 451460
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210012
- Nanjing First Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710065
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610072
- Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
-
-
Yunnan
-
Kunming, Yunnan, Kina, 650102
- Fuwai Yunnan Cardiovascular Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.
Beskrivning
Inclusion Criteria:
- Subject is 18 years or older
- Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
- Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
- Provide signed informed consent prior to the study participation
Exclusion Criteria:
- Valve implantation is contraindicated per the IFU
- Requires planned multiple valve replacement/ repair
- Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
- Estimated Life expectancy< 12 months
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
EDWARDS INSPIRIS RESILIA Aortic Valve
Subjects who were treated with the INSPIRIS RESILIA aortic heart valve. |
Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Subject's Occurrence Rate of Study Valve Related Death
Tidsram: 10 Years
|
The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death. |
10 Years
|
|
Subject's Occurrence Rate of Structural Valve Deterioration
Tidsram: 10 Years
|
The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation. |
10 Years
|
|
Subject's Occurrence Rate of Re-operation on the Study Valve
Tidsram: 10 Years
|
The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room. |
10 Years
|
|
Subject's Occurrence Rate of Major Bleeding
Tidsram: 10 Years
|
The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding. |
10 Years
|
|
Subject's Occurrence Rate of Thromboembolic Events
Tidsram: 10 Years
|
The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event. |
10 Years
|
|
Subject's Occurrence Rate of Stroke
Tidsram: 10 Years
|
The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans. |
10 Years
|
|
Subject's Occurrence Rate of Transient Ischemic Attack
Tidsram: 10 Years
|
The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration. |
10 Years
|
|
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Tidsram: 10 Years
|
The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis). |
10 Years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Subject's Average Mean Gradient at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Mean gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Peak Gradient at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Peak gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Effective Orifice Area evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area Index at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Tidsram: 10 Years
|
Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography |
10 Years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 2021-09
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data will not be available to other researchers.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .